CareDx Inc (CDNA) CEO Peter Maag Sells 80,000 Shares

CareDx Inc (NASDAQ:CDNA) CEO Peter Maag sold 80,000 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $31.11, for a total transaction of $2,488,800.00. Following the sale, the chief executive officer now owns 408,406 shares of the company’s stock, valued at $12,705,510.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Peter Maag also recently made the following trade(s):

  • On Monday, March 11th, Peter Maag sold 50,000 shares of CareDx stock. The shares were sold at an average price of $34.23, for a total transaction of $1,711,500.00.

Shares of CDNA opened at $33.65 on Thursday. The company has a market cap of $1.36 billion, a P/E ratio of -25.69 and a beta of 1.09. CareDx Inc has a twelve month low of $10.31 and a twelve month high of $39.38.



CareDx (NASDAQ:CDNA) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.03). The business had revenue of $25.98 million for the quarter, compared to the consensus estimate of $24.27 million. CareDx had a negative net margin of 51.21% and a negative return on equity of 52.93%. On average, equities analysts expect that CareDx Inc will post -0.52 EPS for the current year.

Several large investors have recently added to or reduced their stakes in the company. Ladenburg Thalmann Financial Services Inc. raised its position in shares of CareDx by 35.8% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,648 shares of the company’s stock valued at $83,000 after purchasing an additional 698 shares during the period. M&T Bank Corp bought a new position in shares of CareDx in the first quarter valued at approximately $232,000. SEI Investments Co raised its position in shares of CareDx by 4.5% in the first quarter. SEI Investments Co now owns 39,633 shares of the company’s stock valued at $1,249,000 after purchasing an additional 1,704 shares during the period. Goldman Sachs Group Inc. raised its position in shares of CareDx by 42.0% in the first quarter. Goldman Sachs Group Inc. now owns 586,916 shares of the company’s stock valued at $18,500,000 after purchasing an additional 173,460 shares during the period. Finally, Essex Investment Management Co. LLC bought a new position in shares of CareDx in the first quarter valued at approximately $699,000. 87.75% of the stock is currently owned by institutional investors.

Several brokerages recently weighed in on CDNA. BidaskClub raised shares of CareDx from a “hold” rating to a “buy” rating in a research report on Tuesday. Zacks Investment Research lowered shares of CareDx from a “hold” rating to a “sell” rating in a research report on Thursday, May 9th. HC Wainwright raised shares of CareDx from a “neutral” rating to a “buy” rating and raised their price objective for the company from $30.00 to $43.00 in a research report on Thursday, May 9th. Piper Jaffray Companies raised their price objective on shares of CareDx from $42.00 to $50.00 and gave the company an “overweight” rating in a research report on Thursday, May 9th. Finally, TheStreet raised shares of CareDx from a “d” rating to a “c” rating in a research report on Tuesday, April 2nd. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $40.17.

COPYRIGHT VIOLATION NOTICE: “CareDx Inc (CDNA) CEO Peter Maag Sells 80,000 Shares” was originally posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://dakotafinancialnews.com/2019/05/16/caredx-inc-cdna-ceo-peter-maag-sells-80000-shares.html.

CareDx Company Profile

CareDx, Inc, a transplant diagnostics company, together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic solutions for transplant patients worldwide. The company develops and provides a diagnostic surveillance testing solution for heart and kidney transplant recipients.

Featured Article: Why do companies issue convertible shares?

Insider Buying and Selling by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.